



STERIS plc (STE)

Updated June 27th, 2024, by Yiannis Zourmpanos

Key Metrics

Current Price:	\$216	5 Year CAGR Estimate:	12.1%	Market Cap:	\$21.6 B
Fair Value Price:	\$229	5 Year Growth Estimate:	10.0%	Ex-Dividend Date:	09/05/2024 ¹
% Fair Value:	94%	5 Year Valuation Multiple Estimate:	1.2%	Dividend Payment Date:	09/23/2024 ²
Dividend Yield:	1.0%	5 Year Price Target	\$368	Years Of Dividend Growth:	14
Dividend Risk Score:	A	Retirement Suitability Score:	D	Rating:	Buy

Overview & Current Events

STERIS plc (STE) is a global leader in infection prevention and other procedural products and services. Founded as Innovative Medical Technologies in Ohio in 1985, the company was later renamed STERIS in 1987. STERIS operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The company has a strong history of acquisitions, including American Sterilizer Company in 1987 and Amsco International in 1996, which expanded its product line for healthcare and sterilization. STERIS has a market capitalization of more than \$23 billion and a solid history of paying dividends.

On May 8th, 2024, the company announced financial results for the fourth quarter of fiscal year 2024. STERIS reported Q4 non-GAAP EPS of \$2.58, beating market estimates by \$0.17, and revenue of \$1.5 billion, which was up 10%. Total revenues for the full fiscal year increased by 12% to \$5.5 billion, while constant currency organic revenue climbed 10% to \$5.0 billion.

The revenue in the Healthcare segment increased by 14% to \$1.01 billion, driven nearly entirely by significant gains in Capital Equipment, Consumables, and Service revenues. Additionally, Applied Sterilization Technologies (AST) revenue of \$250.9 million represented a 5% increase, and the Life Sciences sales of \$160.6 million increased by 2%. In Dental, now a discontinued operation, revenue was held flat at \$103.8 million.

Lastly, operations provided net cash of \$973.3 million in the fiscal year, while free cash flow was \$620.3 million. Forward-looking, STERIS expects revenues for fiscal 2025 to increase between 6.5% and 7.5%, with adjusted earnings per diluted share between \$9.05 and \$9.25.

Growth on a Per-Share Basis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
EPS	\$2.25	\$1.56	\$1.28	\$3.39	\$3.55	\$4.76	\$4.63	\$2.48	\$1.07	\$3.81	\$9.15	\$14.74
DPS	\$0.90	\$0.98	\$1.09	\$1.21	\$1.33	\$1.45	\$1.57	\$1.69	\$1.84	\$2.03	\$2.08	\$3.35
Shares³	59.4	70.7	85.5	85.0	84.6	84.8	85.2	97.5	99.7	98.8	100.0	134.8

STERIS plc operates in a growing healthcare industry that will positively influence its revenues over the long term. In addition, it has a strong track record of growth through acquisitions that helped expand its product offerings and geographical reach. For example, the acquisition of Cantel Medical expanded its product portfolio in infection prevention.

The most significant development of STERIS plc in 2023 was the completion of several tuck-in acquisitions. These acquisitions expanded their product and service offerings in the AST and Healthcare segments. The total aggregate consideration for these acquisitions was approximately \$49.8 million, including a potential contingent consideration of \$7.3 million. This development allowed STERIS to enhance its capabilities and further strengthen its position in the market.

¹ Estimated ex-dividend date.

² Estimated dividend payment date.

³ The shares are in millions.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



STERIS plc (STE)

Updated June 27th, 2024, by Yiannis Zourmpanos

STERIS plc has reported strong growth in the past five years with an EPS CAGR of 29.5%. As a result, we have slightly increased our EPS forecast for 2025, using the midpoint of the management's estimate at \$9.15. Thus, with a forecasted annual growth of 10.0%, the projected EPS in 2030 is \$14.74. STE has consistently increased its DPS but at a slower growth for the last two years. However, we expect the DPS to remain on a rising trajectory through 2030.

Valuation Analysis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	Now	2030
Avg. P/E	30.5	20.1	18.5	20.5	22.6	25.7	27.8	27.6	194.8	55.4	23.6	25.0
Avg. Yld.	1.3%	1.4%	1.3%	1.2%	1.0%	0.9%	0.8%	0.8%	0.9%	0.9%	1.0%	0.9%

STERIS plc trades at a forward P/E of 23.6, close to its normalized long-term average P/E of around 26.0. STERIS trades below its historical valuation multiples, but we consider a P/E of 25 as a fair reflection of the stock's valuation, suggesting a target price of \$368 by 2030.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
Payout	40%	63%	85%	36%	37%	30%	34%	68%	172%	53%	23%	23%

STERIS plc is a leading provider of infection prevention and other healthcare solutions. Its competitive advantage lies in its ability to offer a comprehensive range of products and services that enable healthcare facilities to improve patient outcomes while reducing costs. STERIS plc has also demonstrated resilience during recessions, supported by its steady EPS performance during the 2007 recession. The company has a manageable debt-to-equity ratio of around 53.6%, indicating a healthy balance sheet. This financial stability and competitive edge position STERIS plc for long-term success in the healthcare industry.

Final Thoughts & Recommendation

STERIS' stock has dropped since our last report, and we remain confident that the acquisition synergies will materialize and be reflected in the company's financials in the following years. Thus, following the pullback, we upgrade STE to a buy rating premised upon the 12.1% annualized total returns for the medium-term, derived from the forecasted earnings-per-share growth of 10.0%, 1.0% dividend yield, and a valuation headwind.

Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



STERIS plc (STE)

Updated June 27th, 2024, by Yiannis Zourmpanos

Income Statement Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Revenue	1,622	1,850	2,239	2,613	2,620	2,782	3,031	3,108	4,585	4,958
Gross Profit	650	774	895	1,026	1,093	1,175	1,320	1,343	2,016	2,160
Gross Margin	40.0%	41.8%	40.0%	39.3%	41.7%	42.2%	43.6%	43.2%	44.0%	43.6%
SG&A Exp.	381	493	627	682	632	670	717	731	1,503	1,299
Operating Profit	220	227	212	285	400	442	538	545	426	759
Op. Margin	13.6%	12.3%	9.5%	10.9%	15.3%	15.9%	17.7%	17.6%	9.3%	15.3%
Net Profit	129	135	111	110	291	304	408	397	244	107
Net Margin	8.0%	7.3%	4.9%	4.2%	11.1%	10.9%	13.5%	12.8%	5.3%	2.2%
Free Cash Flow	123	161	128	251	292	350	376	450	397	395
Income Tax	59	74	60	74	63	64	91	121	72	52

Balance Sheet Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Total Assets	1,887	2,097	5,346	4,924	5,200	5,073	5,441	6,574	11,424	10,820
Cash & Equivalents	153	168	249	283	202	221	320	221	348	209
Acc. Receivable	314	325	472	483	528	565	586	609	799	928
Inventories	155	161	193	198	206	208	264	315	575	695
Goodwill & Int.	748	861	3,280	2,956	3,161	2,928	2,922	3,924	7,733	6,835
Total Liabilities	846	1,024	2,308	2,114	1,983	1,887	2,023	2,683	4,879	4,735
Accounts Payable	102	99	140	133	136	153	149	157	226	280
Long-Term Debt	493	621	1,568	1,478	1,316	1,183	1,151	1,651	3,088	3,079
Total Equity	1,039	1,072	3,023	2,799	3,206	3,178	3,405	3,881	6,532	6,077
D/E Ratio	0.48	0.58	0.52	0.53	0.41	0.37	0.34	0.43	0.47	0.51

Profitability & Per Share Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Return on Assets	7.1%	6.8%	3.0%	2.1%	5.7%	5.9%	7.8%	6.6%	2.7%	1.0%
Return on Equity	13.1%	12.8%	5.4%	3.8%	9.7%	9.5%	12.4%	10.9%	4.7%	1.7%
ROIC	8.7%	8.4%	3.5%	2.5%	6.6%	6.8%	9.1%	7.9%	3.2%	1.1%
Shares Out.	59.7	85.9	85.0	84.8	84.5	84.9	85.4	100.1	100.0	100.3
Revenue/Share	27.15	30.81	31.45	30.35	30.57	32.55	35.39	36.18	46.63	49.46
FCF/Share	2.06	2.68	1.80	2.92	3.41	4.09	4.39	5.24	4.04	3.94

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.